Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 220

1.

Development of heparin antagonists with focused biological activity.

Shenoy S, Harris RB, Sobel M.

Curr Pharm Des. 1999 Dec;5(12):965-86. Review.

PMID:
10607857
[PubMed - indexed for MEDLINE]
2.

Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model.

Hulin MS, Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Downing LJ, Stanley JC.

Lab Anim Sci. 1997 Apr;47(2):153-60.

PMID:
9150494
[PubMed - indexed for MEDLINE]
3.

A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.

Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Tejwani S, Hulin MS, Stanley JC.

J Surg Res. 1996 Jun;63(1):280-6.

PMID:
8661211
[PubMed - indexed for MEDLINE]
4.

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Hirsh J, Raschke R.

Chest. 2004 Sep;126(3 Suppl):188S-203S.

PMID:
15383472
[PubMed - indexed for MEDLINE]
5.
6.

Neutralization of enoxaparine-induced bleeding by protamine sulfate.

Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR.

Thromb Haemost. 1990 Apr 12;63(2):271-4.

PMID:
2163553
[PubMed - indexed for MEDLINE]
7.

Low molecular weight protamine: a potential nontoxic heparin antagonist.

Byun Y, Singh VK, Yang VC.

Thromb Res. 1999 Apr 1;94(1):53-61.

PMID:
10213181
[PubMed - indexed for MEDLINE]
8.

PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.

Chang LC, Lee HF, Chung MJ, Yang VC.

Bioconjug Chem. 2005 Jan-Feb;16(1):147-55.

PMID:
15656586
[PubMed - indexed for MEDLINE]
9.

Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep.

Montalescot G, Zapol WM, Carvalho A, Robinson DR, Torres A, Lowenstein E.

Circulation. 1990 Nov;82(5):1754-64.

PMID:
2171807
[PubMed - indexed for MEDLINE]
10.

Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans.

Schick BP, Gradowski JF, San Antonio JD, Martinez J.

Thromb Haemost. 2001 Mar;85(3):482-7.

PMID:
11307819
[PubMed - indexed for MEDLINE]
11.

Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine.

Byun Y, Chang LC, Lee LM, Han IS, Singh VK, Yang VC.

ASAIO J. 2000 Jul-Aug;46(4):435-9.

PMID:
10926141
[PubMed - indexed for MEDLINE]
12.

[Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Harenberg J, Giese C, Knödler A, Zimmermann R, Schettler G.

Klin Wochenschr. 1986 Nov 17;64(22):1171-5. German.

PMID:
3807263
[PubMed - indexed for MEDLINE]
13.

Management of thrombotic and cardiovascular disorders in the new millenium.

Fareed J, Hoppensteadt DA, Bick RL.

Clin Appl Thromb Hemost. 2003 Apr;9(2):101-8. Review.

PMID:
12812377
[PubMed - indexed for MEDLINE]
14.

Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal.

DeLucia A 3rd, Wakefield TW, Andrews PC, Nichol BJ, Kadell AM, Wrobleski SK, Downing LJ, Stanley JC.

J Vasc Surg. 1993 Jul;18(1):49-58; discussion 58-60.

PMID:
8326659
[PubMed - indexed for MEDLINE]
15.

In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.

Kuziej J, Litinas E, Hoppensteadt DA, Liu D, Walenga JM, Fareed J, Jeske W.

Clin Appl Thromb Hemost. 2010 Aug;16(4):377-86. doi: 10.1177/1076029610366439. Epub 2010 May 11.

PMID:
20460347
[PubMed - indexed for MEDLINE]
16.

In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine.

Doutremépuich C, Bonini F, Toulemonde F, Bertrand H, Bayrou B, Quilichini R.

Semin Thromb Hemost. 1985 Jul;11(3):318-22.

PMID:
4048954
[PubMed - indexed for MEDLINE]
17.

Survival of heparins, oral anticoagulants, and aspirin after the year 2010.

Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.

Semin Thromb Hemost. 2008 Feb;34(1):58-73. doi: 10.1055/s-2008-1066025. Review.

PMID:
18393143
[PubMed - indexed for MEDLINE]
18.

Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.

Schick BP, Maslow D, Moshinski A, San Antonio JD.

Blood. 2004 Feb 15;103(4):1356-63. Epub 2003 Oct 23.

PMID:
14576044
[PubMed - indexed for MEDLINE]
Free Article
19.

A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.

Hulin MS, Wakefield TW, Andrews PC, Wrobleski SK, Stoneham MD, Doyle AR, Zelenock GB, Jacobs LA, Shanley CJ, TenCate VM, Stanley JC.

J Vasc Surg. 1997 Dec;26(6):1043-8.

PMID:
9423721
[PubMed - indexed for MEDLINE]
Free Article
20.

Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes.

Cook JJ, Niewiarowski S, Yan Z, Schaffer L, Lu W, Stewart GJ, Mosser DM, Myers JA, Maione TE.

Circulation. 1992 Mar;85(3):1102-9.

PMID:
1537108
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk